Shots:
- The US FDA has granted IND clearance to ACE723 for the initiation of P-I trial to treat patients with unresectable or metastatic hepatocellular carcinoma (HCC)
- The P-I study will assess ACE723’s safety, tolerability, dose-limiting toxicities, PK & preliminary antitumor activity in above-mentioned pts, with dose-escalation portion of establishing recommended dose for further development & potential expansion cohorts
- ACE723 is a GPC3-targeted dual-payload ADC developed using Acepodia’s AD2C platform; Acepodia also submitted an IND application for ACE723 to China’s NMPA in Aug 2026
Ref: PRnewswire | Image: Acepodia | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
